lung-cancer

COPD lung disease may actually boost immunotherapy responses in lung cancer patients.

NSCLC patients with COPD respond better to anti-PD-1 immunotherapy. COPD-driven epithelial remodeling expands CXCL14+ basal-like tumor cells, which recruit CXCL9+ macrophages via CXCL14-CXCR4 signaling, amplifying cytotoxic T cell infiltration. This tumor-macrophage axis predicts pathological…

COPD lung disease may actually boost immunotherapy responses in lung cancer patients.

Key Findings

NSCLC patients with COPD show superior anti-PD-1 responses
COPD epithelial remodeling expands CXCL14+ tumor cells
CXCL14-CXCR4 signaling recruits CXCL9+ macrophages
Amplified cytotoxic T cell infiltration predicts pathological response

Implications

COPD status could become a positive predictive biomarker for NSCLC immunotherapy. Activating this axis in non-COPD patients may sensitize them to immunotherapy.

Caveats

Editorial commentary; abstract-only. Underlying study details not described. COPD carries health burdens that complicate overall prognosis.

Source: Med — 2026-04-10

Landmark DCIS trial, CRC microbiome & AML combos

Two themes cut across this week’s 236 posts. The first is de-escalation: researchers are building rigorous evidence that patients can safely do less — skip lymph node surgery, forgo radiotherapy, watch pre-invasive lesions instead of cutting them out. The landmark result here is a randomized trial confirming that active surveillance

Colorectal Cancer Microbiome Discovery Platform

Analysis of 9,000+ patients revealed that only colorectal cancer — not other cancer types — consistently harbors distinct microbial communities, suggesting the gut microbiome has a unique relationship with colorectal carcinogenesis that could be exploited for diagnostics and treatment.

GBM Tumor Microenvironment Drug Target Atlas

Non-cancerous brain support cells were found to promote glioblastoma growth through paracrine signaling, and blocking this communication dramatically slowed tumor growth — revealing that GBM's microenvironment contains targetable vulnerabilities that are being systematically overlooked by drug…

BET Inhibitor Target Selectivity Database

BRD2 and BRD4 have fundamentally distinct functions — BRD2 prepares genes for activation while BRD4 triggers transcription — meaning that pan-BET inhibitors have been disrupting gene regulation in counterproductive ways, and the field now needs selective BRD4 inhibitors.

COPD lung disease may actually boost immunotherapy responses in lung cancer patients.

Key Findings

Implications

Caveats

Read more

Landmark DCIS trial, CRC microbiome & AML combos

Colorectal Cancer Microbiome Discovery Platform

GBM Tumor Microenvironment Drug Target Atlas

BET Inhibitor Target Selectivity Database